## Annexure-1

## Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

## Part-A- Details of the Acquisition

Name of the Target Company (TC)	Bliss GVS Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	See attached Schedule for breakdown of funds under the management of FMR LLC and its direct and indirect subsidiaries		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Ltd. BSE Ltd. Metropolitan Stock Exchange of India Ltd		
Details of the acquisition as follows	Number	% w.r.t.total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:  a) Shares carrying voting rights b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others) c) Voting rights (VR) otherwise than by equity shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	5,072,327	4.92%	N/A

e) Total (a+b+c+d)	5,072,327	4.92%	-
, ,	· · ·		

Data il a di a mala ilia			
Details of acquisition			
a) Shares carrying voting rights acquired	417,308	0.40%	N/A
b) VRs acquired otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
e) Total (a+b+c/-d)	417,308	0.40%	-
After the acquisition, holding of acquirer along with PACs			
of:			
a) Shares carrying voting rights	5,489,635	5.32%	N/A
b) VRs otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
e) Total (a+b+c+d)	5,489,635	5.32%	-

Mode of acquisition (e.g. open market /public issue / rights issue /preferential allotment /inter-se transfer/ encumbrance, etc.)	Market Purchase
Salient featues of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc	N/A
Date of acquisition of/ date of receipt of intimation of allotment of shares /VR/ warrants/ convertible securities/any other instrument that entitles the acquirer to receive shares in the TC	07 February 2018

Equity share capital / total voting capital of the TC before the said acquisition	103,146,667
Equity share capital/ total voting capital of the TC after the said acquisition	103,146,667
Total diluted share/voting capital of the TC after the said acquisition	N/A

	Fund	Shares held	% of shares and voting rights held
	FID LP STK K6 PRIN ALL SEC SUB	172,327	0.17
Funds under the management of FMR LLC and	FID LOW PRICE STK PRIN ALL SEC	4,600,000	4.45
its direct and indirect subsidiaries	FID SRS INTRINSIC OPP FND	100,000	0.10
	FID LP STK CP PRALSC SB T16852	617,308	0.60
Total		5,489,635	5.32

Signature of the acquirer / Authorised Signatory

Kelvin Lo

Head of Regulatory Reporting, Asia Pacific

Duly authorized under Powers of Attorney by and on behalf of FMR LLC and FIL Limited

Place: C/O FIL Asia Pte Ltd, Level 21, 88 Queensway, Admiralty, Hong Kong

Date: 09 February 2018

Note:

(\*) Total share capital/voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 5 of the listing Agreement.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.